current recommendations and future perspectives
Dunja Urbančič (Avtor), Flaka Pasha (Avtor), Alenka Šmid (Avtor), Irena Mlinarič-Raščan (Avtor)

Povzetek

Despite great therapeutic advances in the field of biologics, small synthetic molecules such as thiopurines, including azathioprine, mercaptopurine, and thioguanine, remain an important therapeutic pillar in the treatment of inflammatory bowel disease, other autoimmune disorders, and cancer. This review presents the latest guidelines for thiopurine administration, highlighting the importance of individualized therapy guided by pharmacogenomics. It emphasizes dose adjustment based on nudix hydrolase 15 (NUDT15) and thiopurine S-methyltransferase (TPMT) genotype, alongside thiopurine S-methyltransferase activity and thiopurine metabolic profile. In addition, the article takes a critical look at emerging research in the field of thiopurine pharmacogenomics featuring novel genetic markers and technological developments in genetic testing. Finally, the potential of integrated approaches that combine genetic, metabolic, and clinical factors to further individualize thiopurine therapy is highlighted.

Ključne besede

thiopurines;TPMT;NUDT15;personalized medicine;therapeutic drug monitoring;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.02 - Pregledni znanstveni članek
Organizacija: UL FFA - Fakulteta za farmacijo
UDK: 61-027.552
COBISS: 206023171 Povezava se bo odprla v novem oknu
ISSN: 1846-9558
Št. ogledov: 11
Št. prenosov: 0
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarni jezik: Slovenski jezik
Sekundarne ključne besede: tiopurini;TPMT;NUDT15;terapevtsko spremljanje zdravil;Personalizirana medicina;NUK;
Vrsta dela (COBISS): Članek v reviji
Strani: str. 355-381
Letnik: ǂVol. ǂ74
Zvezek: ǂno. ǂ3
Čas izdaje: 2024
DOI: 10.2478/acph-2024-0030
ID: 25250388